StreetInsider.com News Articles

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 16 Jun 2026 16:05:00 -0400

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 134,141 restricted stock units (“RSUs”) to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 16 Jun 2026 16:05:00 -0400

The 2023 Inducement Plan is used exclusively for

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 16 Jun 2026 16:05:00 -0400

The 2023 Inducement Plan is used exclusively for

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 16 Jun 2026 16:05:00 -0400

The 2023 Inducement Plan is used exclusively for

Form 25-NSE Quantum-Si Inc Filed by: Nasdaq Stock Market LLC

Wed, 10 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260610/26630411.html

Form 25-NSE Quantum-Si Inc Filed by: Nasdaq Stock Market LLC

Wed, 10 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260610/26630411.html

Quantum-Si partners with Cell Signaling Technology for protein analysis

Wed, 10 Jun 2026 08:00:42 -0400

Quantum-Si Incorporated (NASDAQ: QSI) announced a partnership with Cell Signaling Technology to develop and validate protein sequencing and post-translational modification analysis on its Proteus single-molecule protein sequencing platform.

The collaboration will integrate Cell Signaling Technology's post-translational modification detection and immunoaffinity enrichment capabilities with Quantum-Si's Proteus workflows. The partnership aims to enable site-resolved detection and quantitation of proteins and post-translational modifications for research applications.

Cell Signaling Technology specializes in recombinant monoclonal antibodies, kits, and services for scientific research. The company developed PTMScan proteomics technology, which combines post-translational modification-specific immunoaffinity enrichment with mass spectrometry and bioinformatics.

The collaboration will proceed in two phases. In the

Quantum-Si and Cell Signaling Technology Partner to Advance Post-Translational Modification Analysis on Proteus™

Wed, 10 Jun 2026 08:00:00 -0400

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced a partnership with Cell Signaling Technology (“CST”) to advance and validate next-generation protein sequencing and analysis of post-translational modifications (“PTM”) on the Proteus™ single-molecule protein sequencing platform. The partnership will focus on integrating CST’s PTM detection and immunoaffinity enrichment expertise with Quantum-Si’s Proteus workflows to enable site-resolved detection and quantitation of proteins and PTMs for research applications.